2018
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Abstract: Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).
Search citation statements
Paper Sections
Select...
3,588
1,413
823
95
Citation Types
129
4,512
21
57
Year Published
2000
2026
Publication Types
Select...
4,743
249
243
126
Relationship
140
5,221
Authors
Journals
Cited by 5,038 publications
(4,719 citation statements)
References 32 publications
129
4,512
21
57
“…The present study also showed that the possibility of serious adverse events of third‐generation EGFR‐TKIs was significantly higher than that of first‐generation drugs, which was inconsistent with the results of previous study 13,40 . Looking back on the studies included in the analysis of adverse events comparing EGFR‐TKIs and placebo, the experiment design of Li et al was different from that in the ADAURA and RADIANT studies.…”
Section: Discussioncontrasting
confidence: 99%
“…The present study also showed that the possibility of serious adverse events of third‐generation EGFR‐TKIs was significantly higher than that of first‐generation drugs, which was inconsistent with the results of previous study 13,40 . Looking back on the studies included in the analysis of adverse events comparing EGFR‐TKIs and placebo, the experiment design of Li et al was different from that in the ADAURA and RADIANT studies.…”
Section: Discussioncontrasting
confidence: 99%
“…These results suggest that gefitinib has high cytotoxic effects on only H3255 cells with the L858R mutation, and osimertinib has high cytotoxic effects on H3255 cells and H1975 cells with L858R/T790M double mutations. These results are consistent with previous reports and clinical uses. , As we expected, 9 and 15 have higher cytotoxic effects on H3255 and H1975 than on H441 expressed with the wild-type EGFR. Particularly, 9 and 15 showed similar cytotoxic effects to osimertinib.…”
Section: Resultssupporting
confidence: 93%
“…4 B). These results indicate that the clinical efficacy of osimertinib for patients with EGFR -mutant NSCLC with brain metastases is equal to or greater than that of the other EGFR-TKIs, and our analyzed data were consistent with the previous reports of the FLAURA trial [ 17 , 18 ]. Furthermore, in patients with bone metastasis, the PFS of the osimertinib group was significantly longer than that of the gefitinib/erlotinib group (17.0 vs. 8.6 months; Wilcoxon P < 0.0001 and log-rank P < 0.0001; Fig.…”
Section: Resultssupporting
confidence: 92%
